CBD and Antipsychotic Effects
Small clinical trials suggest CBD may reduce psychotic symptoms; larger studies are needed.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
CBD has a genuine peer-reviewed signal as a potential antipsychotic, but it rests on a handful of small trials using pharmaceutical-grade CBD at 600–1000 mg/day — not the consumer products you see in shops. No large Phase 3 trial has confirmed the early results. Standard antipsychotics remain first-line, with decades of replicated efficacy. CBD is experimental, expensive at therapeutic doses, and carries real risks including drug interactions and liver enzyme elevation.
Plain-language summary
Cannabidiol (CBD) is a non-intoxicating compound found in cannabis. Unlike THC, which can trigger psychotic symptoms in vulnerable people Strong evidence[1], CBD has shown modest antipsychotic signals in small randomized controlled trials (RCTs).
The most-cited evidence comes from two RCTs: one comparing CBD to the antipsychotic amisulpride in 42 acute schizophrenia patients [2], and one testing CBD as an add-on to existing antipsychotics in 88 patients [3]. Both found improvements, but they were small studies. A larger follow-up trial using a lower CBD dose found no benefit [4]. No large Phase 3 confirmatory trial has been conducted. CBD is not approved by the FDA, EMA, or MHRA as an antipsychotic.
This article is not medical advice. If you or someone you know is experiencing psychotic symptoms, talk to a psychiatrist or mental health professional. Do not stop prescribed antipsychotic medication. Do not use consumer CBD products as a substitute for clinical care.
What probably works
Nothing in this category yet. No CBD-for-psychosis use has reached the level of "probably works" — meaning multiple large, independently replicated RCTs with consistent positive outcomes and established safety across diverse populations.
The strongest single finding is the McGuire et al. 2018 trial [3]: a 6-week, multi-site RCT of 88 patients with schizophrenia receiving 1000 mg/day of CBD added to their existing antipsychotic. Participants showed statistically significant improvements in positive symptoms and clinician-rated overall improvement. Weak / limited This represents genuine peer-reviewed evidence worthy of follow-up, but one positive 88-person trial does not meet the "probably works" threshold. It means: worth taking seriously and studying further.
What might work
CBD as adjunct to antipsychotics in schizophrenia. The McGuire 2018 trial [3] found a modest benefit at 1000 mg/day. A smaller follow-up by Boggs et al. (2018) using 600 mg/day for 6 weeks in 50 patients found no improvement in cognition or symptoms [4]. Weak / limited Dose and duration appear to matter, but the optimal regimen is unknown.
CBD as monotherapy in acute schizophrenia. Leweke et al. (2012) randomized 42 acute schizophrenia patients to CBD (up to 800 mg/day) or amisulpride for 4 weeks [2]. Both groups showed similar clinical improvement; CBD showed fewer side effects (less weight gain, lower prolactin elevation, fewer extrapyramidal symptoms). Weak / limited This trial was never replicated at similar scale and remains the only direct head-to-head comparison published.
CBD in clinical high-risk and prodromal states. Bhattacharyya et al. (2018) administered 600 mg CBD or placebo to 33 clinical-high-risk individuals and measured brain activity using fMRI [5]. CBD normalized activity in regions implicated in psychosis (medial temporal, midbrain, striatum). Weak / limited This is a mechanistic finding, not a clinical outcome; no trial has tested whether CBD reduces conversion to psychotic disorder in at-risk individuals.
Cannabis-induced psychosis. Plausible in theory — CBD appears to blunt some of THC's psychotomimetic effects in experimental settings [1] — but no controlled trials have tested CBD treatment in patients with cannabis-induced psychotic disorder. Weak / limited
What doesn't work or has weak evidence
Low-dose consumer CBD products. Published research used 600–1000 mg/day of pharmaceutical-grade, third-party tested CBD. Typical retail CBD oils deliver 10–50 mg per serving and often carry inaccurate labeling [6]. There is no evidence that consumer-grade CBD products—at the doses people typically take—treat psychosis. No data
CBD-rich cannabis flower or "high-CBD strains." No clinical trials have tested smoked or vaporized high-CBD cannabis for psychosis. Such products typically contain THC as well, which can worsen psychotic symptoms Strong evidence[1]. Inhaled cannabis is not the intervention that was studied. No data
CBD for negative symptoms or cognition in schizophrenia. Boggs et al. (2018) found no cognitive improvement at 600 mg/day [4]. Other small studies show mixed or negative results. Weak / limited
CBD for bipolar disorder with psychotic features. Zuardi et al. (2010) reported one open-label case series with unclear benefit [7]. No randomized controlled trials exist. No data
Consumer CBD for any psychiatric condition. Independent laboratory testing has repeatedly documented mislabeled potency and THC contamination in retail CBD products [6]. For someone with psychosis vulnerability, unexpected THC exposure is a documented risk. Strong evidence
What we don't know
- Long-term effects. All published RCTs run 4–6 weeks. No data exist on CBD as a maintenance antipsychotic over months or years, or on relapse rates during discontinuation.
- Optimal dose and dose-response. 600 mg/day showed no benefit in one trial [4]; 1000 mg/day worked in another [3]. The dose-response relationship is unmapped. Whether doses between 600–1000 mg/day produce a gradient effect is unknown.
- Mechanism of action. CBD does not bind dopamine D2 receptors, the target of all approved antipsychotics. Candidate mechanisms include enhancement of anandamide signaling via FAAH inhibition, 5-HT1A agonism, and TRPV1 activation [8]. The actual antipsychotic mechanism in humans remains unconfirmed.
- Predictors of response. No biomarkers or baseline clinical characteristics have been validated to identify which patients are likely to respond to CBD.
- Drug interactions in psychiatric populations. CBD inhibits CYP3A4 and CYP2C19 [9], which metabolize many antipsychotics, benzodiazepines, and anticonvulsants. Real-world pharmacokinetic interactions during co-prescription are under-studied.
- Safety at high doses over time. Liver enzyme elevation is documented in Epidiolex (FDA-approved CBD) trials and post-marketing reports [10]. Long-term safety of 1000 mg/day in antipsychotic-treated populations is not established.
Comparison with standard antipsychotics
Standard antipsychotics (risperidone, olanzapine, amisulpride, aripiprazole, clozapine, quetiapine) have decades of replicated efficacy across hundreds of trials and are first-line treatment for schizophrenia in every major guideline including NICE and the American Psychiatric Association [11]. Their well-known adverse effects include weight gain, metabolic syndrome, sedation, extrapyramidal symptoms, tardive dyskinesia, and prolactin elevation [11].
CBD's appeal in research is that the Leweke trial suggested rough equivalence to amisulpride with a cleaner side-effect profile [2]. If this held up in larger trials, it would represent a meaningful therapeutic addition. It has not been tested in larger trials.
Practically, the comparison today is lopsided: approved antipsychotics have proven efficacy, are available, and are usually covered by insurance or public health systems. CBD as an antipsychotic is experimental, expensive at therapeutic doses (pharmaceutical-grade CBD at 1000 mg/day is not low-cost), not prescribed for this indication, and carries unquantified long-term risks.
Risks and side effects
CBD is generally well-tolerated at therapeutic doses but is not side-effect-free:
- Liver enzyme elevation. Documented in Epidiolex trials and post-marketing surveillance, particularly at doses ≥1000 mg/day and with concurrent valproate [10]. Baseline and periodic liver function tests are recommended for long-term use.
- Sedation and fatigue. Common at multi-hundred-milligram doses, though often mild.
- Drug interactions. CYP3A4 and CYP2C19 inhibition can raise blood levels of co-administered antipsychotics, benzodiazepines, anticonvulsants, and other drugs [9]. Clinical outcomes of such interactions in psychiatric patients are not well-characterized.
- Gastrointestinal effects. Diarrhea, appetite suppression, or nausea reported in trials.
- Product contamination and mislabeling. Consumer CBD is poorly regulated. Independent testing has repeatedly found mislabeled potency and THC contamination [6]. For someone vulnerable to psychosis, unexpected THC is a documented risk factor. Strong evidence
- Delaying effective treatment. The largest clinical risk is using CBD instead of a proven antipsychotic during an acute episode. Untreated psychosis is associated with worse long-term functional and structural brain outcomes Strong evidence[12].
- Interactions with cannabis use. CBD itself does not produce psychosis, but concurrent THC use undermines any protective effect and increases psychosis risk [1]. Strong evidence
Bottom line and not-medical-advice notice
CBD has a genuine peer-reviewed signal as a potential antipsychotic, based on small RCTs using pharmaceutical-grade CBD at 600–1000 mg/day, often combined with existing antipsychotics. It is not approved for psychosis by any regulatory agency. Consumer CBD products do not deliver research doses and are not the same intervention.
This article is not medical advice. It summarizes published peer-reviewed evidence. Decisions about treating psychosis must be made with a qualified psychiatrist or mental health professional. Do not start, stop, or change any psychiatric medication based on this article. If you are experiencing hallucinations, delusions, disorganized thinking, or other psychotic symptoms, contact a mental health professional immediately or, in a crisis, call emergency services.
Sources
- Peer-reviewed Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764–774.
- Peer-reviewed Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry. 2012;2(3):e94.
- Peer-reviewed McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. American Journal of Psychiatry. 2018;175(3):225–231.
- Peer-reviewed Boggs DL, Surti T, Gupta A, et al. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia: a randomized placebo controlled trial. Psychopharmacology. 2018;235(7):1923–1932.
- Peer-reviewed Bhattacharyya S, Wilson R, Appiah-Kusi E, et al. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(11):1107–1117.
- Peer-reviewed Bonn-Miller MO, Loflin MJE, Thomas BF, et al. Labeling Accuracy of Cannabidiol Extracts Sold Online. JAMA. 2017;318(17):1708–1709.
- Peer-reviewed Zuardi AW, Crippa JA, Dursun SM, et al. Cannabidiol was ineffective for manic episode of bipolar affective disorder. Journal of Psychopharmacology. 2010;24(1):135–137.
- Peer-reviewed Davies C, Bhattacharyya S. Cannabidiol as a potential treatment for psychosis. Therapeutic Advances in Psychopharmacology. 2019;9:2045125319881916.
- Peer-reviewed Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine. 2019;8(7):989.
- Government U.S. Food and Drug Administration. Epidiolex (cannabidiol) prescribing information. 2018.
- Government National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. 2014, updated 2014.
- Peer-reviewed Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-at-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70(1):107–120.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- CBD and Trazodone — What we know about combining cannabidiol with the sleep and antidepressant drug trazodone...
- "CBD Has No Side Effects" — The wellness industry's favorite CBD talking point is wrong — here's what controlled trial...
- The Grapefruit Warning and CBD — CBD inhibits liver enzymes, raising drug levels similarly to grapefruit juice.
- THC:CBD Ratios and Effects — How the balance between THC and CBD in a cannabis product shapes its psychoactivity, side...